Lenvatinib 10 mg

DRUG3 trials

Sponsors

Eisai Inc., MedSIR, Chang Gung Memorial Hospital

Conditions

Healthy VolunteersHigh Risk of RecurrenceMetastatic Thymic CarcinomaThymoma Type B3

Early Phase 1

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

RecruitingNCT06327269

Chang Gung Memorial HospitalHigh Risk of Recurrence

Start: 2021-04-01End: 2026-12-31Target: 40Updated: 2024-04-18

Phase 1

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

CompletedNCT02723630

Eisai Inc.Healthy Volunteers

Start: 2013-07-31End: 2013-08-31Updated: 2019-03-14

Phase 2

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

CompletedNCT04710628

MedSIRMetastatic Thymic Carcinoma, Thymoma Type B3

Start: 2021-09-21End: 2026-02-16Updated: 2026-02-19

Related Papers

Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.

2025-09-01